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Antibiotic synthesis by bacterial cultures is one of the most exploited biological pathways of the 
microbial world, and for good reason. All antibiotics that are currently used in modern medicine 
have their origins as by-products of bacterial secondary metabolism. Today, technology has 
allowed advances in areas of antibiotic research and development that have led to alterations 
and the production of semi-synthetic derivatives of antibiotics first isolated from bacterial 
cultures. The important of these antibiotic products cannot be understated in the treatment of 
infectious diseases, and as multidrug resistance rises in emerging pathogens, the continued 
discovery and isolation of new antibiotics from bacteria is ever important. This is why it is 
important to understand and analyze the mechanisms and optimal conditions that induce 
antibiotic production by various bacterial species. More specifically, the mechanism by which 
Streptomyces griseus is coaxed into producing the antibiotics streptomycin and cycloheximide, 
actual research methods aimed at optimizing antibiotic production by S. griseus, and future 
research induction of secondary metabolism are analyzed. 
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Introduction 
Microorganisms abundantly inhabit nearly every surface on the planet. In doing so, they 
inevitably face challenges ranging from harsh environments to invading microbes competing for 
the same nutrients and space. Bacteria and other microorganisms have colonized the Earth for 
billions of years, and as a result, have developed and inherited several adaptations to defend 
themselves against such stressors in their environment. As a domain, the genome of bacteria is 
incredibly malleable, and these microbes take advantage of this plasticity by readily acquiring 
DNA and adaptations from neighboring bacteria (Wilson et al. 2011). This allows entire bacterial 
populations to adapt to environmental shifts quickly. One beneficial adaption is their ability to 
turn to secondary metabolism in times of stress. Secondary metabolism is a state of growth 
induced by unfavorable environmental conditions in which the products of metabolism differ 
from ordinary growth in that they are meant to help the microbe outcompete and survive 
amongst other organisms or harsh conditions. One of the metabolic products that result from 
the induction of secondary metabolism is an antibiotic (Martin and Demain 1980). The 
production of an antibiotic in the presence of an invading neighbor microbe is done with the 
hope that the invading microbe is susceptible to the antibiotic and will therefore be eliminated 
by its production. There are many microbes that are capable of producing antibiotics as a 
secondary metabolite; one such microbe is Streptomyces griseus. In order to stimulate bacteria 
to produce an antibiotic secondary metabolite in a laboratory environment, another microbe, 
or challenge microbe, is placed in the same environment - this creates a co-culture. Using a co­
culture with the original microbe plus a challenge microbe will increase the antibiotic or 
secondary metabolite synthesis (Pettit 2009). The optimization of this process is crucial because 
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nearly every antibiotic used in modern medicine originated or is a derivative of an antibiotic 
produced by a microbe. Therefore, the mechanisms that regulate secondary metabolism, the 
conditions that promote antibiotic production, laboratory techniques, and research methods 
involving co-cultures that promote and optimize the induction of secondary metabolism in 
Streptomyces griseus will be discussed in this paper. 
Secondary Metabolism 
Natural resources are at the forefront of competition between microbial species, and 
their availability can determine the dominating species in a community. There is a resource 
ration model of competition, which states that the dominate taxon of a particular environment 
depends on the availability of a limiting nutrient, the individual demand for that nutrient, and 
the rate of consumption of the nutrient (Hibbing et al. 2010). In other words, the species that 
predominates a particular niche will fluctuate with the availability of a particular nutrient. While 
specific nutrient availability may be a large factor in determining the microbial composition of a 
certain environment, the microbes themselves have the ability to tip the balance in their favor. 
Many species have developed mechanisms to enhance their nutrient acquisition in an effort to 
outcompete neighboring populations under stressful conditions (Hibbing et al. 2010). One 
mechanism employed by bacteria is going into a state of secondary metabolism induced by 
harsh conditions. 
An important aspect to understand with regards to antibiotic production is secondary 
metabolism and its divergence from primary metabolism. A primary metabolite is a product of 
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primary metabolism, and is generally essential to life. These are produced under normal 
conditions, in an environment where the cell or organism is able to thrive. In contrast, a 
secondary metabolite is a product of metabolism that is not required by the organism for 
exponential growth. Secondary metabolites are produced in response to a stressful 
environment, and generally function to help the organism's survival (Martin and Demain 1980). 
It would seem that microbes are only programmed to produce secondary metabolites, such as 
antibiotics, under specific conditions such as when their growth rate drops below a particular 
level (Martin and Demain 1980). This mechanism was most likely produced to conservatively 
deal with competitive pressures seen in a natural environment where resources may be scarce, 
and the production of antibiotics can inhibit or kill any competing microorganisms. 
In addition to the difference in function to the bacterium, primary and secondary 
metabolites are each produced at predictable stages in a bacterial population's growth, which 
follows a defined series of growth stages: the lag phase, exponential or log phase, stationary 
phase, and eventually death. The lag phase is the time period after initial inoculation of a 
culture in which there is no apparent growth or division. It is assumed that the bacterial cells 
are synthesizing and replicating the necessary proteins and enzymes in preparation for division 
during lag phase (Monod 1949). Exponential or log phase is the next period, and is marked by 
an exponential growth pattern as the cells divide via binary fission to double the colony size at a 
particular rate (Monod 1949). It is during this phase that a bacterial culture will produce its 
primary metabolites. Following the growth or exponential phase is the stationary phase in 
which division rate ceases. When microorganisms are placed in/on a particular medium, they 
reach a point at which they have exhausted available nutrients, experience an accumulation of 
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metabolic waste products, and/or run out of space for additional growth (Monod 1949). It is 
during the stationary phase in which microbes are challenged in their environment that they 
begin to produce secondary metabolites in an effort to combat the growth limiting factors they 
may experience. Antibiotic production occurs in stationary phase for reasons besides the 
developing stressful conditions of the phase - many of the species that produce antibiotics are 
actually susceptible to the antibiotic they produce with they are still growing (Martin and 
Demain 1980). Once the bacteria reach a certain point, they enter death phase. In this phase 
the number of viable cells drops as dramatically as they arose - at an almost exponential rate 
(Monod 1949). It is important to note that if growth of specified, antibiotic producing cultures is 
not stopped before this phase, the antibiotic will most likely be degraded. Microbial growth 
easily fluctuates depending on environmental conditions, and for clinical and research 
purposes, methods of promoting and extending stationary growth of a particular bacterium are 
essential to optimizing antibiotic yield. 
Streptomyces griseus 
A microorganism of specific interest for its antibiotic products is Streptomyces griseus. S. 
griseus typically inhabits soils as a saprophyte, degrading remains of other organisms (Challis 
2003). It is the Gram positive soil bacterium that is responsible for the characteristic earthy 
smell of soil. As a bacterium that produces a mycelium, it more closely resembles the 
morphology seen by many filamentous fungi, and it is known for the production of aerial 
hyphae when grown on solid, or agar media (Bibb 2005). This bacterium is also non-motile, 
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which means that it had to evolve ways to combat nutrient limitations and competition rather 
than escape the stressors. As a result,S. griseus is largely responsible for many of the natural 
antibiotic products used today, even some anticancer metabolites (Wiley et al 2011). This 
particular characteristic makes it a popularly researched microorganism. 
Streptomycin and its production by s. griseus 
The actual initiation of secondary metabolism and production of the antibiotic is 
controlled genetically. The enzymes that induce antibiotic production are typically repressed 
during their microorganism's growth phase, and are only active when the growth rate drops 
below that predetermined level. In general, the enzymes that enable to the production of 
antibiotics are called antibiotic synthetases, and it is believed that the delayed production of 
antibiotics is due to the inhibition of these synthetases. It is believed that there are two 
enzymes important for the streptomycin biosynthesis pathway in Streptomyces griseus: 
amidinotransferase and streptidine kinase. Both of these were observed to be repressed during 
the -organism's growth phase, but produced just prior to the production of streptomycin 
(Martin and Demain 1980). In addition to the streptomycin biosynthesis specific enzymes, there 
are a class of extracellular signals called y-butyrolactones that are widely produced by 
Streptomycetes and are believed to play an important role in the onset of secondary 
metabolism; the y-butyrolactone specific to 5. griseus is known as A-factor (Bibb 2005). A-factor 
is an important inducer for stimulating the production of streptomycin by Streptomyces griseus 
(Martin and Demain 1980). Its role Ln the stimulation of the streptomycin biosynthesis pathway 
8 
is significant considering cultures only need to be exposed to A-factor for a few minutes, 
washed, and they are still able to produce streptomycin. Cultures that are not exposed to A­
factor within forty-eight hours of inoculation are not stimulated to produce streptomycin 
(Martin and Demain 1980). It was also shown that exposure to this A-factor caused a significant 
number of mutated strains of S. griseus to regain the ability to produce streptomycin (Martin 
and Demain 1980). It was shown that this A-factor of S. griseus is actually required to bind to a 
cytoplasmic protein allowing for adpA transcription. The product, AdpA, is then required for the 
transcription of strR, which is the known regulatory gene of streptomycin production (Bibb 
2005). Essentially, A-factor is required for the start of an activation pathway culminating in the 
production of streptomycin. In summary, it would seem that secondary metabolism and the 
production of antibiotics is the result of regulatory cascades. These cascades are initiated by a 
number of possible environmental signals, all leading to their own specific pathway and 
regulatory genes that control specific secondary metabolism products. 
The antibiotic streptomycin first isolated from Streptomyces griseus is active against a 
variety of bacterial types including Gram negative and Gram positive bacteria as well as acid­
fast bacteria. This antibiotic is ineffective in treating infections from anaerobic bacteria, fungi, 
or viruses (Waksman 1952). Additionally, streptomycin is actually most potent on young, 
actively dividing bacterial cultures rather than older cultures, but its activity is not completely 
diminished with older cultures as it is with some other antibiotics (Waksman 1952). 
Streptomycin originally received the most praise in its success in treating tuberculosis. The 
search for a treatment for tuberculosis is actually what sparked the investigation into the 
antibiotic secondary metabolites of S. griseus by Waksman. 
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The actual mechanism of streptomycin involves its inhibition of protein synthesis by 
inactivating the 305 ribosome thereby blocking the ribosome cycle {Luzzatto et al. 1968}. Both 
the 305 and 50S ribosomal subunits are required for the production of proteins, but 
streptomycin is capable of diminishing the movement of ribosomes, meaning the two subunits 
would not be able to bind to an mRNA sequence and produce protein {Luzzatto et al. 1968}. 
Streptomycin as a by-product of secondary metabolism in S. griseus was an important discovery 
as i~ has several medicinal uses today including its use as a viable alternative to pathogens that 
have become resistant to penicillin. 
Cycloheximide and its production by S. griseus 
Cycloheximide is a type of glutarimide antibiotic known for its antifungal properties. 
Essentially, the mode of action of cycloheximide involves the inhibition of protein synthesis via 
80S ribosomes {Obrig et al. 1971}. In utilizing the 80S ribosome, cycloheximide exerts its effects 
on protein synthesis by inhibiting peptide elongation and, more commonly, initiation via the 
donor ribosomal site on the 80S ribosome. 
When S. griseus was tested to determine the conditions and mechanisms that control 
cycloheximide production, it was noted that utilization of glucose corresponded with start of 
cycloheximide production. In addition the exhaustion of glucose supplies also corresponded 
with the termination of cycloheximide production as well as the degradation of any 
cycloheximide that had accumulated up until that point {Kominek 1975}. These observations 
seemingly conclude that glucose plays an apparent role in the production of cycloheximide by 
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Streptomyces griseus. In addition, cycloheximide itself plays a role in its biosynthesis pathway­
the accumulation of cycloheximide most likely serves as a factor in the repression or feedback 
inhibition of the mechanism that controls cycloheximide production (Kominek 1975). This study 
also sought to show that the production of cycloheximide by 5. griseus is a highly regulated 
mechanism in that it does not waste energy in the overproduction of the antibiotic. Increasing 
concentrations of cycloheximide were added to the flasks containing the cycloheximide 
producing S. griseus, and that rate of cycloheximide production was recorded. It was observed 
that cycloheximide production dropped dramatically with the increase of cycloheximide 
concentration added to the flask supporting the idea that S. griseus will not indulge in the 
overproduction of the antibiotic (Kominek 1975). Overall, it can be concluded that glucose 
concentrations directly correspond to the rate of synthesis of cycloheximide by S. griseus­
maximum cycloheximide production corresponds to the greatest glucose concentration. The 
decrease in production also corresponds to the depletion of available glucose, and the 
degradation of the antibiotic occurs after complete exhaustion of glucose (Kominek 1975). 
With the observation that the accumulation of cycloheximide has a negative correlation 
with its production, product (cycloheximide) removal while the microbe is still in culture was 
proposed to improve the yield of the secondary metabolite. This is done the hope to reduce the 
feedback regulation that leads to decreased cycloheximide production, removal of products to 
decrease toxicity rates, and to prevent the degradation of the antibiotic, which may occur of 
the bacteria is allowed grow in a stressed environment for too long (Payne and Wang 1989). 
Implications of evidence that the removal of the cycloheximide by-product will increase the 
efficacy of the rate at which S. griseus is able to convert glucose to cycloheximide include 
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reduced cost to profit margin when seeking the production of this antibiotic (Payne and Wang 
1989). It is therefore proposed thatin order to achieve the maximum cyclohexamide 
production, experimental protocols must be in place to either remove the antibiotic by-product 
or to stop its production at its peak. 
The importance of cycloheximide cannot be understated for antibiotics with antifungal 
activity are not overly common. Since cycloheximide exhibits this activity, its use is not as 
common or as well researched as one of the other antibiotic products of 5. griseus, 
streptomycin. 
Experimental Techniques Using Co-Cultures 
It was seen that 5. griseus may be stimulated to produce both streptomycin and 
cycloheximide, which are both important antibiotics, so it is important to understand and 
discover methods to maximize the efficacy at which Streptomyces griseus is able to produce 
these two antibiotics. The use of specific challenge microbes in a co-culture with Streptomyces 
griseus can force it to produce certain antibiotics. Co-cultures are used to mimic a natural 
environment in which a microbe's environment may be invaded by a neighboring pathogen. 
Therefore, the use of co-cultures stimulates enhances the production of antibiotics by 
promoting secondary metabolism. In regards to co-cultures that enhance the production of 
secondary metabolites by 5. griseus, a number have been identified, which include Penicillium 
chrysogenum, Fusarium oxysporum, Rhizobium leguminosarum, and the Streptomycetes 
isolates Strepto8 and StreptoBlue2 (Bowser 2013). In addition to co-cultures, defined media can 
be used to promote slower growth and production of antibiotics as a secondary metabolite 
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directly following inoculation. Defined medium is a growth media that is constructed for a 
particular microbe, and may contain only small amounts of a limiting nutrient to stress the 
microbe (Martin and Demain 1980). 
While defined medium or stressed nutrient conditions may help in the coercion of the 
microbe to switch to secondary metabolism, the use of co-cultures in a production medium 
ensure that switch as well as direct the products of the microbe's secondary metabolism. 
Previous research has determined that the challenge microbe Strepto8 is capable of inducing 
the biosynthesis pathways of both streptomycin and cycloheximide, which made it a target for 
further study (Bowser 2013). 
Materials and Methods 
The method by which each of these microbes are grown, stimulated to produce 
antibiotics, and quantification of their antibiotic production is a lengthy and meticulous process 
as the microorganisms themselves as well as several of the tests employed are sensitive to even 
the slightest variation. Each of the microorganisms used in these experiments were first 
cultured on solid agar media, and an isolated colony from that culture is placed in liquid seed 
media flasks where they are allowed to grow for varying lengths. The see medium (ATCC 
medium #172) was (giL): 10.0 gluco-se, 20.0 soluble starch, 5.0 yeast extract, 5.0 NZamine A, 1.0 
CaC03 . Flasks containing sOmL of this seed media were prepared, autoclaved, inoculated with 
the challenge microbe, and placed on a shaker at 210rpm for one week prior to the start of the 
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production media. Forty-eight hours before the start of the production media,S. griseus was 
started in a seed culture prepared the same way as before. 
Following these required time periods, production media was prepared for inoculation. 
The production media, which was a modified Kominek, was comprised of (giL): 60.0 glucose, 
15.0 white bean flour, 2.5 yeast extract, 5.0 (NH4hS04, 8.0 CaC03, 4.0 NaCl, 0.2 KH 2P04. This too 
was prepared, autoclaved, inoculated, and placed on a shaker at 210rpm for a week. 5. griseus 
was first placed in the production media flasks, where secondary metabolism was induced, and 
allowed to grow for twenty-four hours before the introduction of a challenge microbe. The 
production flasks then went for a week from the initial inoculation with 5. griseus before 
growth was stopped. This time frame was determined to be the ideal time to promote the 
greatest antibiotic production as well as ending the experiment before nutrients were 
exhausted and the antibiotics were degraded (Bowser 2013). 
Antibiotic production is then assessed using bioassays and the Kirby-Bauer protocol for 
each antibiotic. The bioassays are conducted by first creating seeded agar plates with 
microorganism that are susceptible to cycloheximide and streptomycin - Saccharomyces 
cerevisiae and Bacillus subtilis, respectively. Saccharomyces cerevisiae was grown on PDA plates 
before being suspended in a 0.85% NaCl, or physiological saline solution. B. subtilis, was grown 
in TSB for 16 hours prior to pouring plates - tubes were vortexed often to prevent pellicle 
formation. The seeded agar plates were TGY agar: (giL): 3.0 glucose, 3.0 tryptone, 3.0 yeast 
extract, 1.0 K2 HP04, and 15.0 agar to which either a 0.5%(v/v) yeast suspension or 2mL to 200mL 
of B. subtilis were added. 
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The Kirby-Bauer technique was then utilized to determine the diameter of inhibition 
zones of the treatment flasks, which were compared to a standard curve that was done at the 
same time (Bowser 2013). For each repetition for each treatment, 20llL were placed onto a 
6mm sterile disc that was placed on the seeded agar plate, and allowed to incubate at their 
proper temperatures for twenty-four hours. For the cycloheximide assay, samples first had to 
be diluted to a 1:20 dilution before plating. This meant 30llL of the treatment sample was 
placed in 570llL of distilled water and 20llL of that solution was then placed on the 6mm sterile 
disc. 
In order to determine the actual antibiotic concentrations that were produced from the 
antibiotics, a standard curve was run at the same time of the bioassay. A standard curve was 
run for both cycloheximide and streptomycin from known, purified stock solutions. A known 
concentration of 2000llg/mL was used to begin a 1:2 serial dilution until the concentration 
reached a satisfactory range ending with a Tll dilution. Following the dilution 20llL of each 
dilution was placed, in duplicate, on 6mm sterile paper discs and on their respective plates. It is 
important to run the standard curves on the same day as the treatments were plated to 
accurately determine the antibiotic concentrations because they will be adjusted to the same 
conditions. 
The measured inhibition zone diameters were placed in the equation created by this 
graph to determine the cycloheximide concentrations of all the treatments. These 
concentrations were then used for further statistical analysis to determine whether co-cultures 
produced a Significant increase in the production of cycloheximide. In order to measure any 
significant differences and qualify those differences into groups, the analysis of variance, or 
15 
ANOVA, test was used. More specifically, the One-Way ANOVA in combination with the Tukey 
and Fisher/LSD tests to separate any significantly different treatments into groups. In order to 
perform these tests, the data collected must pass at least two other tests to determine whether 
the data itself meets the required assumptions to even perform an ANOVA test - normal 
distribution and equal variances. 
The significance of this procedure is that it is a controlled experiment in which 
Streptomyces griseus is stimulated to produce antibiotics for a set time period. The bioassay 
protocol following that growth period allows for the quantification and direct comparison of 
the efficiency of antibiotic production under different treatment conditions because it is 
compared with a standard curve for each antibiotic. The effects of various co-cultures as wells 
as other possible treatments on the stimulation of antibiotic production can be assessed using 
this method, which will hold implications for optimized antibiotic production both 
experimentally and commercially. 
Results 
The data collected from the two standard curves was used to conduct their own 
separate linear regression analyses. From this linear regression analysis, a best fit line was 
created for cycloheximide, and the equation of that line was then used to relate inhibition zone 
diameter and antibiotic concentration allowing for the determination of the antibiotic 
concentrations created by each treatment group (Figure 1). 
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Figure 1. Fitted line plot from linear regression analysis of inhibition zone diameter (mm) in 
relation to the log10 of cycloheximide concentration in the standard curve 
Diameter = 27.42 + 9.505 Log 10 of Conc. 
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Once tests of normal distribution for each treatment group in cycloheximide production 
(Fig·ures 2 and 3) and tests for equal variances (Figure 4) were passed, the One-Way ANOVA was 
conducted to analyze data from cycloheximide production for significant differences. 
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Figure 2. Probability plots of cycloheximide production by 5. griseus, Strepto8, StreptoBlue2 
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Figure 3. Probability plot of cycloheximide production R. leguminosarum, P. chrysogenum, F. 
oxysporum 
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Figure 4. Tests for equal variances for cycloheximide production 
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*The Bartlett's and Levene's tests both test for the Null hypothesis that all group variances are 
equal by providing a P-value that reflects the Null hypothesis. 
The P-values provided in figure 4 are greater than 0.10, indicating equal variances, and 
that the assumptions for ANOVA have been met. The One-Way ANOVA test was now conducted 
using the data concerning cycloheximide production. The overall P-value for the One-Way 
ANOVA test conducted on cycloheximide production by S. griseus and various challenge 
microbes is 0.014, which indicated a strong likelihood that there will be at least two significantly 
different groups. 
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Table 1. Results of cycloheximide production by 5. griseus + challenge microorganisms from 
One-Way ANOVA. 
Treatment N Mean (~g/mL) Tukey Fisher/LSD 
5. griseus + P. chrysogenum 5 693.5 A A 
S. griseus + 5treptoBlue2 5 646.4 A B A B 
5. griseus + 5trepto8 5 611.4 A B A B 
5. griseus + F. oxysporum 5 498.8 A B B C 
5. griseus + R. leguminosarum + 5trepto8 5 495.6 A B B C 
5. griseus 5 418.2 B C 
*For Tukey and Fisher/LSD tests, each group with a different letter is significantly different (P ~ 
0.05) from another 
Results from One-Way ANOVA of cycloheximide production are shown in Table 1. When 
looking at any significant increases in cycloheximide production from the co-cultures compared 
to just 5. griseus, the Fisher/LSD portion of the One-Way ANOVA show that 5. griseus + P. 
chrysogenum,5. griseus + 5treptoBlue2, and 5. griseus + 5trepto8 all show a significant increase. 
While the 5. griseus + F. oxysporum and 5. griseus + R. leguminosarum + 5trepto8 co-cultures 
may show an increase in cycloheximide production, it is not large enough to be a significant 
increase from that of 5. griseus alone (Table 1). Unlike the Fisher/LSD test, the Tukey test only 
shows that one co-culture,S. griseus + P. chrysogenum, showed significant cycloheximide 
increase from 5. griseus (Table 1). 
20 
To better visualize cycloheximide production by the co-cultures used in this experiment, 
the boxplot shown in Figure 5 displays the average cycloheximide production from each of the 
five repetitions for each treatment group. 
Figure 5. Resulting boxplots from the One-Way ANOVA of cycloheximide production 
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The same methods were conducted on the data collected regarding streptomycin 
production by S. griseus and its co-cultures. The inhibition zone diameters themselves were 
smaller than those observed with cycloheximide - even though streptomycin is the antibiotic S. 
griseus is best known for. 
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The data from the standard curve for streptomycin was, again, used to conduct a linear 
regression analysis. This data was also used to construct a best fit like to create an equation 
that was used to determine the actual streptomycin concentrations produced in by each 
treatment based on the diameter of their inhibition zone (Figure 6). 
Figure 6. Fitted line plot from linear regression analysis of inhibition zone diameter (mm) in 
relation to the loglO of streptomycin concentration in the standard curve 
Diameter = 16.19 + 10.84 Log10 of Cone. 
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Once the equation shown in Figure 6 was used to determine the streptomycin 
concentrations of all the treatment groups, the tests for normal distribution and equal variance 
were conducted on the antibiotic concentration data. Figures 7 and 8 show that the data 
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passed the normal distribution requirement and Figure 9 shows the data for streptomycin 
displays equal variance, so the One-Way ANOVA was conducted. 
Figure 7. Probability plots of streptomycin production by 5. griseus, 5. griseus + 5treptoBlue2J 
and 5. griseus + 5treptoB 
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Figure 8. Probability plot of streptomycin production 5. griseus + P. chrysogenum, 5. griseus + F. 
oxysp()rum, and 5. griseus + R. leguminosarum + 5treptoB 
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*For P-values that are above 0.10 the data is considered to be normally distributed 
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Figure 9. Test for equal variances among the data for streptomycin production 
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*The Bartlett's and Levene's tests both test for the Null hypothesis that all group variances are 
equal by providing a P-value that reflects the Null hypothesis. 
According to Figure 9, the P-values for both the Bartlett's Test and Levene's Test were 
greater than 0.10, so there was no evidence to disprove the Null hypothesis and it was safely 
assumed there were equal variances among the data for streptomycin. The One-Way ANOVA 
test was conducted using the data collected for streptomycin production. 
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Table 2. Results of streptomycin production by 5. griseus + challenge microorganisms from One-
Way ANOVA. 
Treatment N Mean (~g/mL) Tukey Fisher/LSD 
5. griseus + R. leguminosarum + 5trepto8 5 588.4 A A 
5. griseus + 5trepto8 5 435.6 A A B 
5. griseus + P. chrysogenum 5 400.8 A B 
5. griseus + 5treptoBlue2 5 392.2 A B 
5. griseus + F. oxysporum 5 376.1 A B 
5. griseus 5 354.1 A B 
*For Tukey and Fisher/LSD tests, each group with a different letter is significantly different (P $ 
0.05) from another 
The One-Way ANOVA test results are shown in Figure 1. According to the Fisher/LSD 
portion of the ANOVA, there was only one treatment that was able to significantly increase the 
production of streptomycin as a co-culutre - 5. griseus + R. leguminosarum + 5trepto8. The 
Tukey portion of the ANOVA found that none of the treatments led to a significant increase in 
streptomycin production. In fact, The Tukey's test did not mark any improvement of 
streptomycin production, whereas the Fisher/LSD portion showed the 5. griseus + 5trepto8 co­
culture as having some effect on antibiotic production (Table 2). 
Figure 10 shows the boxplots from the ANOVA test that display a better representation 
of the lack of significant increase in streptomycin with the use of these co-cultures. 
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Figure 10. Resulting boxplots from the One-Way ANOVA of streptomycin production 
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*Each of the treatments included 5. griseus plus the challenge microbe, except for the negative 
control which contained only 5. griseus 
Discussion 
This particular experiment was conducted to determine whether co-cultures had an 
effect on the antibiotic production by 5. griseus, and if they did, which microorganisms 
stimulated the best production of the antibiotics streptomycin and cycloheximide. When 
looking at the results of the One-Way ANOVA, it was clear that the co-cultures used in this 
experiment did have an effect on the production of antibiotics. The different challenge 
mic'robes used here seemed to have a larger effect on the production of cycloheximide rather 
than streptomycin because there were three co-cultures that were able to produce a significant 
increase in antibiotic production over S. griseus alone (according to the Fisher/LSD portion of 
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the One-Way ANOVA): 5. griseus + P. chrysogenum, 5. griseus + 5treptoBlue2, and 5. griseus + 
5trepto8 (Table 1). 
The same challenge microbes and co-cultures were used to analyze the possible 
enhancement of streptomycin production by 5. griseus, but there were slightly different results. 
It seemed that streptomycin production overall lacked in comparison to cycloheximide 
synthesis, and it definitely lacked in its ability to have significant increase in antibiotic 
production over 5. griseus alone. The Fisher/LSD portion of the ANOVA only showed one co­
culture that had a significant increase over 5. griseus: 5. griseus + R. leguminosarum + 5trepto8 
(Table 2). The Tukey portion of the ANOVA test not only determined that there were no 
treatment groups that had a significant increase, but the results show there was not enough of 
an i"ncrease in general to separate any of the groups partially from 5. griseus. 
Considering the co-culture that produced the least significant increase in cycloheximide 
production produced the only significant increase in streptomycin production, it is evident that 
there are different mechanisms taking place in the action of enhancing or even promoting the 
pathways that lead to the synthesis of these two antibiotics. Investigation into the further 
understanding of these mechanisms as well as the by-products that these challenge microbes 
produce will enable a better understanding of the best pairing between antibiotic producing 
microbe and their challenge microbe. 
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Future Research 
The results from the experimental trials co-culturing S. griseus with Strepto8 reveal the 
challenge microbe's ability to successfully promote not just one but two antibiotics as 
secondary metabolites of s. griseus. Further research may include investigation into the 
location and even the specific molecule that is produced by Strepto8 that acts in inducing the 
two antibiotic biosynthesis pathways. In order to narrow down possible locations and identities 
of the inducing molecule of Strepto8, a variety of treatments that extends the protocol for 
previous experiments as well as treatments that test alternative methods (Figure 11). 
One of the first questions is whether the molecule is extracellular or intracellular. The 
traditional protocol requires the challenge microbe must be blended before addition to the s. 
griseus flasks, which means that both intracellular and extracellular molecules will mix. The first 
step would be to add an additional treatment that is unblended before its addition - if the 
molecule is intracellular, it will not be able to exert its effects on s. griseus in the intact, 
un blended treatment. 
From this point, similar treatments may be applied to both blended and 
un blended cultures to provide a more in-depth analysis as well as a certain level of replication 
and control. In order to address whether the stimulating component must be alive to exert its 
effects on s. griseus, portions of both blended and unblended samples should be placed in hot 
water bath for a sufficient amount of time that leads to death. Further determination regarding 
the molecule's presence either in the extracellular or intracellular environment may be 
conducted via a series of centrifugation steps. The supernatant from the first centrifugation of 
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both blended and unblended cultures can be filtered and used as treatments to determine if 
this specific molecule is originally present, or excreted into, the extracellular environment (seen 
with un blended culture) or whether the molecule is initially intracellular and released upon 
blending. The pellet from this first centrifugation is resuspended and two more centrifugations 
separated by resuspensions in physiological saline follow. Repeatedly centrifuging the blended 
and unblended samples serves to wash the material large enough to form a pellet when 
centrifuged. Using the pellet material that is washed and isolated from the unblended culture 
as a treatment will help to determine whether the stimulatory molecule is either the intact cells 
themselves or some mechanism solely involving those intact cells. The pellet material from the 
blended culture helps to determine if the inducing of antibiotic production is directly a result of 
some intracellular component or organelle of the cell rather than some small molecule 
produced within the cell. For any clarification, Figure 11 diagrams the various proposed 
treatments for the determination of the molecule or component produced by Strepto8. All of 
these treatments serve to narrow the possibilities of the type and location of the specific 
molecule produced by Strepto8 that has the ability to induce the simultaneous production of 
streptomycin and cycloheximide by Streptomyces griseus. 
The identification and isolation of the specific molecule or component that directs 5. 
griseus biosynthetic pathways to produce streptomycin and cycloheximide would unlock the 
ability to more directly and efficiently promote the production of those antibiotics. This could 
lead to the direct and calculated use of that particular molecule from Strepto8 to effectively 
maximize the production of not one but two antibiotics possibly in a shorter time frame than 
the current method. 
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Figure 11. Diagram of proposed treatments for the determination of the location and type of 
molecule produced by Strepto8 that induces the biosynthesis pathways in Streptomyces griseus 
that lead to secondary metabolites streptomycin and cycloheximide 
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Conclusion 
The use of bacterial secondary metabolites in the modern world is vast, but the specific 
use of antibiotics from secondary metabolism holds great significance in medicine's battle 
against infectious diseases. The isolation of all antibiotics originates from research into the 
secondary metabolism process of microorganisms. Considering many of the pathogens 
encountered today are developing resistances to current antibiotics, understanding the 
mechanisms behind the induction of secondary metabolism, the conditions required to 
promote varying secondary metabolites, and any processes that lead to the optimization of 
production and isolation of these products is more important than ever. Streptomyces griseus is 
a particular bacterium of interest in this research due to its previously discovered ability to not 
only produce a number of different antibiotics, but also its ability to produce antibiotics with 
antibiotic and antifungal actions. Further research should be conducted in the understanding of 
its already known antibiotic products and the mechanisms of their biosynthetic pathways in 
order to greatly optimize antibiotic production as well as investigation into other conditions and 
challenge microbes that may hold the potential to promote the production of novel antibiotics. 
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